RespireRx Pharmaceuticals Inc (fka RSPI)

[davidal66]

What they need, more than cash, is new management. New blood. A team to examine and rapidly implement faster trials to show POC in more innovative ways, thinking outside of the box. I'm more intrigued and inspired by the technology based on these results and what I know about ADHD trials, and what I know about RD.

Other than a buyout or new management, the one hope would be a comprehensive deal to get this technology or most of it out of their hands. Let them play with a single, obtuse indication like Rett's, but get these compounds into a competent scientific team. I'm being undiplomatic and harsh, but I firmly believe this is the right course of action: either a buyout or a comprehensive deal or two deals(low and high impact) to get these compounds as far away from this management, and as soon as possible.